v. 23 software package (SPSS Inc)
SPSS Inc is a verified supplier 
90
Structured Review
SPSS Inc
v. 23 software package
V. 23 Software Package, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software+package+v%2E23/v+20+software+package/pm37481147-103-7-11
Average 90 stars, based on 1 article reviews
V. 23 Software Package, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software+package+v%2E23/v+20+software+package/pm37481147-103-7-11
Average 90 stars, based on 1 article reviews
v. 23 software package - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration. Article Snippet: Purpose: In several case-studies improved outcomes have been reported after switching from a pro-re-nata (PRN)to a treat-and-extend (T&E)-based therapeutic approach in cases of neovascular age-related macular degeneration (nAMD).. We therefore wished to compare the effects of instigating 2 different protocols in newlydiagnosed nAMD undergoing treatment with Ranibizumab.. Methods: The outcomes of a PRNand a T&E-based regime were retrospectively compared in treatment-naı̈ve eyes under therapy with Ranibizumab for minimally 12 months in a routine clinical setting. Article Title: Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months. Article Snippet: Purpose: Comparative data appertaining to the long-term effects of Aflibercept or Ranibizumab in newly diagnosed cases of neovascular age-related macular degeneration (nAMD) over follow-up periods exceeding 12 months in clinical routine are scarce.. Methods: In this retrospective comparative analysis, a case series of patients with treatment-naı̈ve nAMD and requiring anti-vascular endothelial growth factor (VEGF) therapy in a routine clinical setting were treated with either Aflibercept [Afl (n = 106)] or Ranibizumab [Ran (n = 47)].. During the drug-loading phase, 3 monthly injections were administered. Article Title: Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series Article Snippet: All statistical analyses were performed using the Article Title: Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a "Treat-and-Extend" Regimen. Article Snippet: Purpose: To report outcomes in patients with neovascular age-related macular degeneration (nAMD) after treatment with aflibercept for up to 4 years using a treat-and-extend (T&E) regimen.. Design: Observational study.. Participants: Patients with newly diagnosed nAMD treated with aflibercept in a T&E protocol. |